Hikal Limited
NSE: HIKAL BSE: HIKAL
NSE
423.80
-7.80 (-1.81%)
Prev Close
431.6
Open Price
434
Volume
371,223
Today Low / High
421.5 / 438.15
52 WK Low / High
267.25 / 464.75
Range
403 - 445
BSE
424.20
-7.25 (-1.68%)
Prev Close
431.45
Open Price
391.15
Volume
15,717
Today Low / High
421.9 / 436.6
52 WK Low / High
268.05 / 464.5
Range
403 - 445
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 423.8 (target range: 403 - 445), reflecting a change of -7.8 (-1.80723%). On the BSE, it is listed at 424.2 (target range: 403 - 445), showing a change of -7.25 (-1.68038%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
21 Apr
434.00
-2.35%
17 Apr
433.00
-0.32%
16 Apr
417.70
3.64%
15 Apr
424.40
-2.31%
11 Apr
391.00
7.12%
09 Apr
397.00
-3.41%
08 Apr
398.95
-0.13%
07 Apr
326.35
19.56%
04 Apr
425.65
-5.83%
03 Apr
417.00
2.07%
02 Apr
401.20
4.35%
01 Apr
398.80
0.60%
28 Mar
405.05
-1.38%
27 Mar
397.00
2.03%
26 Mar
408.95
-2.24%
25 Mar
425.00
-4.07%
24 Mar
412.00
2.88%
Hikal Limited Graph
Hikal Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Hikal Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 423.80, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 424.20 | 428.44 | 385.60 - 471.29 |
| 432.68 | 346.15 - 519.22 | ||
| 436.93 | 305.85 - 568.00 | ||
| Bearish Scenario | 424.20 | 419.96 | 377.96 - 461.95 |
| 415.72 | 332.57 - 498.86 | ||
| 411.47 | 288.03 - 534.92 |
Overview of Hikal Limited
ISIN
INE475B01022
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
317,025
Market Cap
52,254,857,850
Last Dividend
1.2
Official Website
IPO Date
2002-07-01
DCF Diff
395.20
DCF
35
Financial Ratios Every Investor Needs
Stock Dividend of HIKAL
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-02-07 | February 07, 25 | 0.6 | 0.6 | 2025-02-08 | 2025-03-05 | |
| 2024-09-04 | September 04, 24 | 0.6 | 0.6 | 2024-09-04 | 2024-10-17 | |
| 2024-02-20 | February 20, 24 | 0.6 | 0.6 | 2024-02-20 | 2024-03-09 | |
| 2023-09-18 | September 18, 23 | 0.6 | 0.6 | 2023-09-19 | 2023-10-26 | |
| 2023-02-14 | February 14, 23 | 0.6 | 0.6 | 2023-02-14 | 2023-03-03 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 1,768.66 Cr | 864.03 Cr | 904.62 Cr | 0.5115 | 0.00 Cr | 61.44 Cr | 149.42 Cr | 69.60 Cr | 5.64 | 267.03 Cr | 0.0394 |
| 2023-03-31 | 2,004.71 Cr | 1,160.02 Cr | 844.69 Cr | 0.4214 | 0.00 Cr | 57.07 Cr | 148.93 Cr | 78.38 Cr | 6.36 | 259.93 Cr | 0.0391 |
| 2022-03-31 | 1,926.03 Cr | 1,042.61 Cr | 883.42 Cr | 0.4587 | 0.00 Cr | 42.62 Cr | 245.24 Cr | 160.50 Cr | 13.02 | 340.42 Cr | 0.0833 |
| 2021-03-31 | 1,707.05 Cr | 947.63 Cr | 759.43 Cr | 0.4449 | 0.00 Cr | 22.53 Cr | 238.61 Cr | 133.14 Cr | 10.80 | 323.62 Cr | 0.0780 |
| 2020-03-31 | 1,505.26 Cr | 1,231.12 Cr | 274.14 Cr | 0.1821 | 48.24 Cr | 21.03 Cr | 191.05 Cr | 84.44 Cr | 6.85 | 255.20 Cr | 0.0561 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 12.70 Cr | 2,487.14 Cr | 1,299.49 Cr | 1,187.6610 Cr | 817.58 Cr | 804.87 Cr | 303.72 Cr | 1,483.00 Cr | 0.00 Cr | 59.35 Cr | 0.40 Cr | 756.6330 Cr |
| 2023-03-31 | 26.73 Cr | 2,385.48 Cr | 1,252.01 Cr | 1,133.4700 Cr | 748.18 Cr | 721.45 Cr | 316.74 Cr | 1,350.27 Cr | 18.29 Cr | 43.64 Cr | -8.61 Cr | 661.5540 Cr |
| 2022-03-31 | 11.44 Cr | 2,213.11 Cr | 1,145.13 Cr | 1,067.9810 Cr | 675.02 Cr | 663.58 Cr | 328.98 Cr | 1,184.76 Cr | 40.82 Cr | 29.00 Cr | 0.64 Cr | 769.1820 Cr |
| 2021-03-31 | 7.64 Cr | 1,913.22 Cr | 979.82 Cr | 933.4020 Cr | 610.25 Cr | 602.61 Cr | 266.70 Cr | 973.49 Cr | 5.18 Cr | -37.58 Cr | -4.05 Cr | 656.7850 Cr |
| 2020-03-31 | 31.68 Cr | 1,767.98 Cr | 951.48 Cr | 816.5020 Cr | 645.86 Cr | 614.18 Cr | 312.46 Cr | 893.19 Cr | 0.00 Cr | 0.00 Cr | 0.76 Cr | 596.3210 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 186.7200 Cr | -173.7450 Cr | -27.0000 Cr | -17.4800 Cr | -14.0270 Cr | 12.7030 Cr | -204.1960 Cr | 95.5050 Cr | 66.5230 Cr | -14.8270 Cr | 11.0200 Cr |
| 2023-03-31 | 315.3090 Cr | -292.3400 Cr | -7.6800 Cr | 12.6890 Cr | 15.2890 Cr | 26.7300 Cr | -302.6200 Cr | 105.3650 Cr | 69.4890 Cr | -12.3300 Cr | 8.2330 Cr |
| 2022-03-31 | 293.7330 Cr | -284.3710 Cr | -5.5580 Cr | 20.4190 Cr | 3.8040 Cr | 11.4000 Cr | -273.3140 Cr | 218.5590 Cr | 66.7470 Cr | -27.1260 Cr | -63.4200 Cr |
| 2021-03-31 | 229.0180 Cr | -156.1960 Cr | -96.8680 Cr | 71.4190 Cr | -24.0470 Cr | 7.6360 Cr | -157.5990 Cr | 206.4250 Cr | -32.9520 Cr | -14.8190 Cr | 39.7650 Cr |
| 2020-03-31 | 284.9300 Cr | -163.7970 Cr | -100.8640 Cr | 126.8980 Cr | 20.2690 Cr | 31.6830 Cr | -158.0320 Cr | 141.9800 Cr | -25.0150 Cr | -23.7830 Cr | 50.5910 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 438.90 Cr | 210.90 Cr | 228.00 Cr | 0.5195 | 38.90 Cr | 17.20 Cr | 1.39 | 75.70 Cr | 0.0392 |
| 2024-09-30 | 450.80 Cr | 201.90 Cr | 248.90 Cr | 0.5521 | 43.20 Cr | 18.30 Cr | 1.48 | 75.30 Cr | 0.0406 |
| 2024-06-30 | 406.80 Cr | 281.20 Cr | 125.60 Cr | 0.3088 | 26.20 Cr | 5.10 Cr | 0.41 | 58.50 Cr | 0.0125 |
| 2024-03-31 | 514.10 Cr | 330.37 Cr | 183.73 Cr | 0.3574 | 62.12 Cr | 33.97 Cr | 2.76 | 94.92 Cr | 0.0661 |
| 2023-12-31 | 447.57 Cr | 297.10 Cr | 150.47 Cr | 0.3362 | 35.79 Cr | 16.14 Cr | 1.31 | 64.80 Cr | 0.0361 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 20.20 Cr | 21.50 Cr | 41.70 Cr | 0.00 Cr | 338.30 Cr | 930.40 Cr | 1,467.30 Cr | 2,460.30 Cr | 1,256.90 Cr |
| 2024-06-30 | -20.88 Cr | 41.76 Cr | 20.88 Cr | 0.00 Cr | 0.00 Cr | 20.88 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 12.70 Cr | 5.49 Cr | 18.19 Cr | 550.34 Cr | 303.72 Cr | 966.61 Cr | 1,483.00 Cr | 2,487.14 Cr | 1,299.49 Cr |
| 2023-12-31 | -36.10 Cr | 72.20 Cr | 36.10 Cr | 0.00 Cr | 0.00 Cr | 36.10 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 10.95 Cr | 37.65 Cr | 48.60 Cr | 0.00 Cr | 367.69 Cr | 894.03 Cr | 1,424.46 Cr | 2,390.85 Cr | 1,245.59 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 5.10 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 33.97 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 16.14 Cr | 57.94 Cr | 0.00 Cr | 0.00 Cr | 57.94 Cr | 94.04 Cr | 36.10 Cr | 0.00 Cr | 57.94 Cr |
| 2023-09-30 | 12.57 Cr | 57.14 Cr | 0.00 Cr | 0.00 Cr | 57.14 Cr | 36.10 Cr | 0.00 Cr | 0.00 Cr | 57.14 Cr |
| 2023-06-30 | 6.92 Cr | 55.46 Cr | 0.00 Cr | 0.00 Cr | 55.46 Cr | 82.43 Cr | 26.97 Cr | 0.00 Cr | 55.46 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2018-06-22 | June 22, 18 | 3:2 |
| 2015-02-27 | February 27, 15 | 5:1 |
| 2003-09-29 | September 29, 03 | 3:2 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,497,390,360.00 | ₹1,539,404.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,891.50 | ₹1,564,008,080,155.00 | ₹717,304.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.60 | ₹1,101,504,496,478.00 | ₹168,941.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.40 | ₹1,067,918,241,168.00 | ₹342,053.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,177.40 | ₹980,907,622,968.00 | ₹1,938,682.00 |
| Lupin Limited | LUPIN | ₹2,009.20 | ₹917,330,458,276.00 | ₹966,589.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹845.35 | ₹850,619,911,900.00 | ₹1,860,605.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,201.20 | ₹697,658,929,968.00 | ₹653,310.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,000.40 | ₹597,872,826,000.00 | ₹97,948.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,368.80 | ₹386,259,126,032.00 | ₹2,163,260.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,423.80 | ₹361,224,068,436.00 | ₹163,712.00 |
| Laurus Labs Limited | LAURUSLABS | ₹640.35 | ₹345,310,338,375.00 | ₹1,671,228.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,679.20 | ₹334,664,498,320.00 | ₹44,703.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,202.20 | ₹306,037,994,912.00 | ₹330,131.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,658.70 | ₹258,221,804,814.00 | ₹100,079.00 |
| Piramal Enterprises Limited | PEL | ₹1,039.85 | ₹234,462,986,345.00 | ₹552,041.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,401.40 | ₹227,698,028,558.00 | ₹264,593.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,727.50 | ₹218,187,500,000.00 | ₹13,476.00 |
| Eris Lifesciences Limited | ERIS | ₹1,382.90 | ₹188,299,218,053.00 | ₹81,150.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,136.00 | ₹168,533,566,400.00 | ₹53,273.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹849.65 | ₹167,009,863,405.00 | ₹223,768.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹829.80 | ₹148,625,361,828.00 | ₹383,129.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹915.95 | ₹145,893,560,183.00 | ₹228,298.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,906.70 | ₹144,931,500,763.00 | ₹146,966.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹480.20 | ₹116,469,494,344.00 | ₹1,207,487.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,223.50 | ₹86,706,866,654.00 | ₹3,571.00 |
| FDC Limited | FDC | ₹430.60 | ₹70,106,024,754.00 | ₹67,489.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹712.85 | ₹64,608,888,867.00 | ₹374,808.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹658.10 | ₹64,356,197,871.00 | ₹163,074.00 |
| Strides Pharma Science Limited | STAR | ₹640.75 | ₹59,053,256,433.00 | ₹243,236.00 |
| Innova Captab Limited | INNOVACAP | ₹915.85 | ₹52,409,452,141.00 | ₹37,786.00 |
| Hikal Limited | HIKAL | ₹423.80 | ₹52,254,857,850.00 | ₹371,223.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹152.84 | ₹49,599,942,480.00 | ₹505,473.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹633.90 | ₹44,630,236,620.00 | ₹75,809.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹799.75 | ₹40,562,604,224.00 | ₹101,985.00 |
| Sequent Scientific Limited | SEQUENT | ₹148.17 | ₹37,087,247,340.00 | ₹527,793.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,179.20 | ₹36,041,821,488.00 | ₹10,217.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.90 | ₹35,087,098,650.00 | ₹40,163.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹361.65 | ₹33,007,795,500.00 | ₹101,872.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.91 | ₹29,540,183,967.00 | ₹4,747,370.00 |
| Suven Life Sciences Limited | SUVEN | ₹127.13 | ₹27,723,712,024.00 | ₹173,057.00 |
| Alembic Limited | ALEMBICLTD | ₹105.35 | ₹27,051,965,791.00 | ₹436,085.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹520.70 | ₹25,021,207,514.00 | ₹37,558.00 |
Key Executives
Senior President of Animal Health & Business Transformation
Mr. Anish Dilip Swadi
Gender: male
Year Born:
President of Human Resources
Mr. Ratish Jha
Gender: male
Year Born:
Head of IP & Quality, Pharmaceuticals
Dr. T. Devanathan
Gender: Not Specified
Year Born:
Head of Sustainability & Corporate EHS
Mansukh Gokalbhai Patel
Gender: Not Specified
Year Born:
MD & Executive Director
Mr. Sameer Jai Hiremath
Gender: male
Year Born: 1974
President of Pharmaceuticals Business
Mr. Manoj Mehrotra
Gender: male
Year Born: 1962
President of Crop Protection
Mr. Vimal Deep Kulshrestha
Gender: male
Year Born: 1965
Chief Financial Officer
Mr. Kuldeep Jain
Gender: male
Year Born:
Founder & Executive Chairman
Mr. Jai Vishwanath Hiremath
Gender: male
Year Born: 1948
Company Secretary & Compliance Officer
Mr. Rajasekhar Reddy Chintakindi
Gender: male
Year Born:
FAQs about Hikal Limited
Who is the CEO of the company?
The CEO is Mr. Jai Vishwanath Hiremath.
What is the current market price of the stock?
The current price is ₹423.80.
What is the 52-week price range?
The range is ₹267.25-464.75.
What is the market capitalization of the company?
The market capitalization is ₹5,225.49 crores.
What is the dividend yield?
The dividend yield is 0.28%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 70.33.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Hikal Limited (ISIN: INE475B01022) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹5,225.49 crores and an average daily volume of 317,025 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹1.2.